Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | TYK2 | P29597 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 6/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.35 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.34 |
| ▸ | DHODH | Q02127 | 1/20 | 0.32 |
| ▸ | CCR1 | P32246 | 1/20 | 0.31 |
| ▸ | CCR8 | P51685 | 1/20 | 0.31 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3405607 | 0.83 | L3MBTL1 (0.46) | MAPTRAB9ANPC1ATMSMN1; SMN2 | |
| SCHEMBL12424756 | 0.76 | TGFBR1 (0.41) | MAPTRAB9ANPC1ATMSMN1; SMN2 | |
| SCHEMBL2328238 | 0.73 | NPC1 (0.37) | MAPTRAB9ANPC1ATMSMN1; SMN2 | |
| SCHEMBL3382263 | 0.71 | IKBKE (0.50) | IDO1IGF1R | |
| SCHEMBL243473 | 0.69 | CCR1 (0.46) | DHODHCCR1CCR8 | |
| SCHEMBL2563617 | 0.67 | RAB9A (0.69) | MAPTRAB9ANPC1ATMSMN1; SMN2 | |
| SCHEMBL38651177 | 0.67 | MAPT (0.63) | MAPTRAB9ANPC1ATMSMN1; SMN2 | |
| SCHEMBL1907360 | 0.67 | MAPT (0.63) | MAPTRAB9ANPC1ATMSMN1; SMN2 | |
| SCHEMBL3660220 | 0.67 | RAB9A (0.50) | MAPTRAB9ANPC1ATMSMN1; SMN2 | |
| SCHEMBL17540994 | 0.66 | HSP90AA1 (0.39) | MAPTRAB9ANPC1SMN1; SMN2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8791113-B2 | 2,4-diaryl-substituted [1,8] naphthyridines as kinase inhibitors for use against cancer | MERCK PATENT GMBH (DE) | 2014-07-29 | — | — | US | disclosed |
| US-8791113-B2 | 2,4-diaryl-substituted [1,8] naphthyridines as kinase inhibitors for use against cancer | MERCK PATENT GMBH (DE) | 2014-07-29 | — | — | US | disclosed |
| US-20130102603-A1 | 2,4-DIARYL - SUBSTITUTED [1,8] NAPHTHYRIDINES AS KINASE INHIBITORS FOR USE AGAINST CANCER | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-04-25 | — | — | US | disclosed |
| US-20130102603-A1 | 2,4-DIARYL - SUBSTITUTED [1,8] NAPHTHYRIDINES AS KINASE INHIBITORS FOR USE AGAINST CANCER | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-04-25 | — | — | US | disclosed |
| WO-2012000595-A1 | 2,4- DIARYL - SUBSTITUTED [1,8] NAPHTHYRIDINES AS KINASE INHIBITORS FOR USE AGAINST CANCER | MERCK PATENT GMBH (DE) | 2012-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130102603-A1 | 2,4-DIARYL - SUBSTITUTED [1,8] NAPHTHYRIDINES AS KINASE INHIBITORS FOR USE AGAINST CANCER | TGFBR1, TAB1, TGFBR2 | MAPT 4149/4885RAB9A 2544/4885NPC1 2454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.